文献速递消化系统肿瘤

局部dMMR结直肠癌PD-1治疗的内镜与影像学结局

Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer.
PubMed 文献 · Eur J Cancer · 2023-09-22

该回顾性分析纳入38例接受新辅助抗PD-1治疗的局部dMMR结直肠癌患者,中位治疗8周期。可评估病例中内镜最佳完全缓解率为45%,影像学完全缓解率为23%。影像学与内镜最佳反应不一致见于54%的可评估患者。中位随访28.2个月,18例手术患者中61%达病理完全缓解。

要点

  • 可评估病例中内镜最佳完全缓解率45%,影像学完全缓解率23%。
  • 28例同时有影像和内镜评估的患者中,15例(54%)最佳反应不一致。
  • 18例手术患者中11例(61%)达病理完全缓解。

核心结论

  • 影像学与内镜之间的反应不一致普遍存在,即使病理缓解,这些检查仍可发现异常。
  • 需要改进临床反应标准。

研究设计与样本

  • 回顾性分析接受至少1周期新辅助抗PD-1治疗的局部dMMR结直肠癌患者,共38例,中位治疗8周期。
  • 按标准化标准回顾内镜、影像学和病理学结局以判定治疗反应。

主要发现

  • 可评估病例中(内镜n=31,影像n=34),内镜最佳完全缓解率为45%,影像学最佳完全缓解率为23%。
  • ≤4周期IO后影像学完全缓解率(n=1)为6%,>4周期IO后(n=7)为44%。
  • 28例同时有影像和内镜评估的患者中,15例(54%)最佳反应不一致。
  • 自IO开始中位随访28.2个月,18例接受手术切除,其中11例(61%)达病理完全缓解。
  • 非手术管理的患者中,尽管达病理完全缓解或IO完成后≥6个月无进展证据,分别有72%和42%的患者影像学和内镜未达完全缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant immune checkpoint blockade (IO) is emerging as a therapeutic option for patients with deficient mismatch repair (dMMR) colorectal cancer (CRC) given high pathological response rates. The aim of the study was to characterise imaging and endoscopic response to IO. METHODS: A retrospective analysis of patients with localised dMMR CRC that received at least one cycle of neoadjuvant anti-PD-1 therapy was conducted. Endoscopy, imaging, and pathological outcomes were reviewed to determine response to treatment according to standardised criteria. RESULTS: Thirty-eight patients had received IO for the treatment of localised CRC (median eight cycles). Among evaluable cases (n = 31 for endoscopy and n = 34 for imaging), the best endoscopic response was complete response (CR) in 45% of cases, and the best radiographic response was CR in 23% of cases. Imaging CR rate after ≤4 cycles of IO (n = 1) was 6% compared to 44% after >4 IO cycles (n = 7). Among 28 patients with imaging and endoscopy available, a discrepancy in best response was noted in 15 (54%) cases. At a median follow-up of 28.2 months from IO start, 18 patients underwent surgical resection of which 11 (61%) had pathological CR (pCR). Despite pCR or no evidence of progression ≥6 months after completion of IO among non-operatively managed patients, 72% and 42% of patients had non-CR on imaging and endoscopy, respectively. CONCLUSIONS: Discrepancies between imaging and endoscopy are prevalent, and irregularities identified on these modalities can be identified despite pathological remission. Improved clinical response criteria are warranted.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Fox DA, Bhamidipati D, Konishi T, et al. Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer. Eur J Cancer. 2023. PMID: 37827065. doi:10.1016/j.ejca.2023.113356

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。